Skip to content

WHWK WHWK Additional Paid-In Capital

Additional Paid-In Capital at other companies

Eli Lilly logo
Eli LillyLLY
$6.92B+0.2%
Pfizer logo
PfizerPFE
$94.77B+1.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$14.4B+9.2%
Gilead Sciences logo
Gilead SciencesGILD
$9.31B+14.3%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.77B+3.2%
OS Therapies logo
OS TherapiesOSTX
$66.72M+75.1%

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's additional paid-in capital?
WHWK (WHWK) reported additional paid-in capital of $491.63M in Q1 2026.
How has WHWK's additional paid-in capital changed year-over-year?
WHWK's additional paid-in capital increased by 2.1% year-over-year, from $481.36M to $491.63M.
What is the long-term trend for WHWK's additional paid-in capital?
Over 4 years (2021 to 2025), WHWK's additional paid-in capital has grown at a 15.1% compound annual growth rate (CAGR), from $279.09M to $489.44M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.